|
11 |
Analyst report: Hana Securities Inc.(25.11.20.) |
Alteogen |
2025-11-20 |
|
10 |
Analyst report: DAOL Investment & Securities(25.11.12.) |
Alteogen |
2025-11-12 |
|
9 |
Analyst report : Kyobo Securities(25.10.15.) |
Alteogen |
2025-10-15 |
|
8 |
Analyst report: CLSA (2025.09.22.) |
Alteogen |
2025-09-22 |
|
7 |
Analyst report: Hana Securities Inc.(25.09.22.) |
Alteogen |
2025-09-22 |
|
6 |
Analyst report: Macquarie (2025.09.22.) |
Alteogen |
2025-09-22 |
|
5 |
Analyst report: Shinhan Securities(25.09.22.) |
Alteogen |
2025-09-22 |
|
4 |
Business Update: Daiichi Sankyo Initiates Phase 1 Clinical Trial for the SC Formulation of Enhertu Using ALT-B4 |
Alteogen |
2025-06-13 |
|
3 |
Business Update: US patent Regstration Schedule for ALT-B4 |
Alteogen |
2025-04-25 |
|
2 |
Business Update: Halozyme’s Lawsuit Against MSD and Our Response |
Alteogen |
2025-04-25 |
